Retraction Note: Letter to Editor, “The effects of dabrafenib and/or trametinib treatment in Braf V600mutant glioma: a systematic review and metaanalysis”

被引：0
|
作者：
Hethesh Chellapandian [1 ]
Sivakamavalli Jeyachandran [1 ]
机构：
[1] Saveetha Dental College and Hospital,Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics
[2] Saveetha Institute of Medical and Technical Sciences (SIMATS),undefined
来源：
Neurosurgical Review | / 48卷 / 1期
关键词：
D O I：
10.1007/s10143-025-03284-9
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF DABRAFENIB plus TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E-MUTATED LOW-GRADE GLIOMA (LGG)
    Wen, Patrick
    De Greve, Jacques
    Mason, Warren
    Hofheinz, Ralf-Dieter
    Dietrich, Sascha
    de Vos, Filip
    van den Bent, Martin
    Mookerjee, Bijoyesh
    Boran, Aislyn
    Burgess, Paul
    Rangwala, Fatima
    Gazzah, Anas
    NEURO-ONCOLOGY, 2018, 20 : 238 - 238
  • [42] An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib
    Abravanel, Daniel L.
    Nishino, Mizuki
    Sholl, Lynette M.
    Ambrogio, Chiara
    Awad, Mark M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E131 - E133
  • [43] Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)
    Kreitman, Robert J.
    Moreau, Philippe
    Hutchings, Martin
    Gazzah, Anas
    Blay, Jean-Yves
    Wainberg, Zev A.
    Stein, Alexander
    Dietrich, Sascha
    de Jonge, Maja J. A.
    Willenbacher, Wolfgang
    De Greve, Jacques
    Arons, Evgeny
    Ravandi, Farhad
    Rangwala, Fatima
    Burgess, Paul
    Mookerjee, Bijoyesh
    Subbiah, Vivek
    BLOOD, 2018, 132
  • [44] Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter
    Huillard, Olivier
    Tenenbaum, Florence
    Clerc, Jerome
    Goldwasser, Francois
    Groussin, Lionel
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5639 - 5639
  • [45] Sarcoid-like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic/chiasmatic glioma
    Wilhelmsson, Mari
    Chun, Foo Jen
    Yeung, Rae S. M.
    Krtizinger, Fiona
    McKeown, Tara
    Coblentz, Ailish
    Ertl-Wagner, Birgit
    Tabori, Uri
    Bartels, Ute
    Das, Anirban
    PEDIATRIC BLOOD & CANCER, 2023,
  • [46] Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)
    Hargrave, D.
    Witt, O.
    Cohen, K.
    Packer, R.
    Lissat, A.
    Kordes, U.
    Laetsch, T. W.
    Hoffman, L.
    Lassaletta, A.
    Gerber, N. U.
    Gilheeney, S.
    Holm, S.
    Kramm, C.
    Sumerauer, D.
    Reitmann, C.
    Russo, M. W.
    Bouffet, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 132 - 132
  • [47] Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E- Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma
    Costa, Ines N.
    Reis, Joana
    Pinheiro, Jorge
    Silva, Roberto
    Fernandes, Catarina
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [48] Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
    Si, Lu
    Zhang, Xiaoshi
    Shin, Sang Joon
    Fan, Yun
    Lin, Chia-Chi
    Kim, Tae Min
    Dechaphunkul, Arunee
    Maneechavakajorn, Jedzada
    Wong, Chi Sing
    Ilankumaran, Palanichamy
    Lee, Dung-Yang
    Gasal, Eduard
    Li, Haifu
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 31 - 38
  • [49] Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
    Fasano, Morena
    Della Corte, Carminia Maria
    Caterino, Marianna
    Pirozzi, Mario
    Rauso, Raffaele
    Troiani, Teresa
    Martini, Giulia
    Napolitano, Stefania
    Morgillo, Floriana
    Ciardiello, Fortunato
    FRONTIERS IN MEDICINE, 2022, 8
  • [50] BUDGET IMPACT ANALYSIS OF DABRAFENIB AND TRAMETINIB COMBINATION THERAPY IN THE TREATMENT OF BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER IN THE UNITED STATES
    Zhou, Z.
    Bensimon, A.
    Cheng, J.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A422 - A422
12345